Mice, gene edited so their GLP1 receptors more closely resemble ours. That edit is why an oral human drug could be tested in them at all.
Staff at NIMH 's Transgenic Core Facility
Illustrative. Not the animals used in this study.
GLP1 Pills May Curb Cravings Through a Brain Circuit No One Had Mapped Before
I've written before about GLP1 drugs and hunger. This is a different story. A new NIH funded study just found a second brain pathway these drugs seem to reach, one tied to wanting rather than needing, and it's specific to the newer oral pill class rather than the injectables most people already know.
- NIH funded researchers at the University of Virginia found that oral GLP1 pills, Eli Lilly's orforglipron and Pfizer's danuglipron, activate the central amygdala, a deep brain reward region, in mice.
- Activating this circuit quieted dopamine release specifically during pleasure driven eating, not hunger driven eating, a separate pathway from the hypothalamus and hindbrain mechanism already established for injectable GLP1s like semaglutide.
- It's mouse only data so far, even with humanized GLP1 receptors, and hasn't been independently replicated yet.
- The same NIH team is already planning follow up studies on whether this circuit also explains reduced cravings for substances beyond food.
The circuit the drug reached. The finding is about where in the brain the signal lands, not about weight on a scale.
Unsplash
Illustrative. Not imaging from this study, which was done in mice.
Hypothalamus and hindbrain
The appetite suppression pathway already established for injectable GLP1s. It tracked separately and did not explain the new effect on its own.
Central amygdala
A desire and reward hub deeper in the brain than these drugs were previously thought to reach. Dopamine release fell specifically while the mice ate palatable, non essential food.
Mice, gene edited so their GLP1 receptors more closely resemble human ones. Not a clinical trial, and not independently replicated.
What the researchers actually did
A team at the University of Virginia, funded by NIH, gene edited mice so their GLP1 receptors more closely resemble human receptors. That step mattered because orforglipron and danuglipron, both oral small molecule GLP1 drugs, are designed for the human receptor, not the native rodent one. The study was published July 25, 2026 in Nature, with NIH's own press release, ScienceDaily, and EurekAlert all independently reporting matching figures.
- 2
- Oral drugs dosed: orforglipron and danuglipron
- 1
- Newly mapped region: the central amygdala
- HUMAN
- Receptors gene edited to resemble ours
- 0
- Clinical trials
What the evidence actually shows
one dials down hunger, the other appears to dial down the pull of eating purely for pleasure
Dosed mice showed activation in the central amygdala, a desire and reward hub deeper in the brain than these drugs were previously thought to reach, along with reduced dopamine release specifically while the mice ate palatable, non essential food. The already known appetite suppression pathway, running through the hypothalamus and hindbrain, tracked separately and didn't explain this new effect on its own. The two mechanisms look distinct: one dials down hunger, the other appears to dial down the pull of eating purely for pleasure.
Honest caveat
This is mouse only data. Even with humanized GLP1 receptors, it hasn't been shown in people, and NIH's own release notes the study was not completed as a clinical trial. There's no independent replication yet either. The dopamine and reward findings describe what happened alongside drug exposure, not proof of exactly how it happens in a human brain, so I wouldn't extrapolate this into "this drug will kill your cravings" claims for actual patients until human studies exist.
What this means for you
If you've wondered why GLP1 drugs seem to quiet the urge to snack and not just the feeling of hunger, this gives that observation an actual mechanism, at least in mice, and at least for the oral small molecule class. It's also a genuine bridge to a storyline I plan to keep watching, since the NIH team is explicitly eyeing follow up studies on cravings for substances beyond food, alcohol and nicotine among them, using the same reward circuit logic.
Primary sources
- Godschall et al., "A brain reward circuit inhibited by next generation weight loss drugs in mice," Nature 654 (2026): 1055. Peer reviewed study, published July 25, 2026.
- NIH and NIDA press release, "Oral small molecule GLP1 drugs penetrate deep into the brain to suppress cravings," July 25, 2026. Official government research agency release.
- Cross corroborated via ScienceDaily and EurekAlert, both reprinting the NIH release with matching figures.
Common questions
Is this the same mechanism as Ozempic?
No. This new reward circuit finding is specific to the oral small molecule GLP1 pills orforglipron and danuglipron. Injectable peptide GLP1 drugs like semaglutide, sold as Ozempic, work primarily through a different, already established hypothalamus and hindbrain pathway. Whether injectable GLP1s also reach this reward circuit wasn't tested here.
Has this been shown in humans?
Not yet. This is mouse only data. Researchers gene edited the mice to carry humanized GLP1 receptors so the human designed drugs would work correctly, but NIH's own release notes the study was not run as a clinical trial. No human imaging data exists yet to confirm the same circuit lights up in people.
Does this mean GLP1 pills could help with cravings beyond food, like alcohol or nicotine?
That's the researchers' own next question, not something this study proved. The NIH team is already planning follow up studies on substance use cravings, since the mechanism they found, dampening dopamine during reward driven wanting, is the same kind of circuit implicated in addiction. That's a hypothesis for future research, not a finding of this paper.
Stay Curious.
Better health isn't found in a single article. It's built through curiosity, evidence, and small discoveries over time. Join thousands exploring longevity, gut health, recovery, nutrition, and the tools that truly make a difference.